| 2026-08-25 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-14 | Press release | Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-11 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-11 | Press release | Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era |
| 2026-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-11 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-10 | Deck | August 2026 Corporate Deck |
| 2026-08-04 | Press release | Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on , at 8:30 AM |
| 2026-07-28 | Press release | Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors |
| 2026-07-28 | 8-K | Form 8-K, Item 5.02 |
| 2026-07-02 | Press release | Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-10 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-22 | Deck | American Society of Clinical Oncology Update – May 2026 |
| 2026-05-21 | Press release | Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by |
| 2026-05-21 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-13 | Press release | Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-11 | Press release | Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-11 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on , at 8:30 AM ET |
| 2026-04-27 | Proxy | Definitive proxy statement |
| 2026-04-03 | Press release | Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-30 | Press release | Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-30 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-30 | Transcript | Q4 FY25 earnings call transcript |
| 2026-03-23 | Press release | Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-19 | Press release | Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of |
| 2026-02-19 | 8-K | Form 8-K, Item 8.01 |
| 2026-01-12 | Press release | Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook |
| 2026-01-12 | 8-K | Form 8-K, Item 8.01 |
| 2025-12-08 | 8-K | Form 8-K, Item 7.01 |
| 2025-12-01 | Press release | Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750m |
| 2025-11-10 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-10 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-13 | Press release | Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R |
| 2025-08-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-12 | 10-Q | Form 10-Q for the quarter ended Jun 30 |